Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.